Implementation of NICE Technology Appraisal Guidance (TAG)

I am writing on behalf of Royal National Institute of Blind People (RNIB) to access information under the Freedom of Information Act 2000. This request relates to our work around preventing avoidable sight loss.

Please note that this request relates to secondary care ophthalmology services.

Many thanks in advance for your assistance.

1. Access to NICE approved treatments in ophthalmology

Is the treatment listed below routinely available to patients according to it’s NICE TAG?

Please could you indicate by putting a cross in the applicable box below and sending the completed table back to RNIB (contact details below). Confirmation (i.e. indicating ‘yes’) means that patients do not have to use Individual Funding Requests to access aflibercept for treating choroidal neovascularisation.

Please put a cross in the relevant box:

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

Royal National Institute of Blind People
A registered charity in England and Wales (no. 226227), Scotland (no. SC039316) and the Isle of Man (no. 1226). Also operating in Northern Ireland. A company incorporated by Royal Charter. Registered in England and Wales (no. RC000500). Registered office 105 Judd Street, London WC1H 9NE
| Aflibercept for treating choroidal neovascularisation |  |
| Technology appraisal guidance [TA486] Published date: 01 November 2017 | X |

Please acknowledge receipt of this request by email and your full response to puja.joshi@rnib.org.uk. Please do not hesitate to contact me if you have any questions.

Links to the NICE guideline on this treatment has been copied below my email signature.